ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2025
Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Influenza vaccine protection and contact patterns among outpatients with influenza-like illness during the 2024-2025 season in China: a test-negative case-control study.Journal of global health · 2026Article
- Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation During the 2024/25 Season in Northern Ireland, UK.Influenza and other respiratory viruses · 2026Article
- Article
- Interim vaccine effectiveness against influenza virus among outpatients, France, October 2025 to January 2026.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Influenza vaccine effectiveness and genetic diversity: insights from end-of-season community surveillance, France, 2024-2025.Emerging microbes & infections · 2025Article
- Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance.Influenza and other respiratory viruses · 2025Article
- Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance.Influenza and other respiratory viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37-46%), with 26% (95% CI: 18-34%) against influenza A and 75% (95% CI: 66-82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13-30%) and among 0-64-year-olds, 60% (95% CI: 56-65%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.